Making a COVID-19 vaccine that works for everyone: ensuring equity and inclusivity in clinical trials
| Autor: | Toby Pepperrell, Pranav Tandon, Molly Pugh-Jones, Sarai Keestra, Florence Rodgers, Kelly Sarsfield, Theo Rashid |
|---|---|
| Přispěvatelé: | Epidemiology and Data Science |
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
Male
medicine.medical_specialty COVID-19 Vaccines media_common.quotation_subject Ethnic group ethnic minorities HV Social pathology. Social and public welfare. Criminology 1117 Public Health and Health Services 03 medical and health sciences 0302 clinical medicine RA0421 Public health. Hygiene. Preventive Medicine HN Social history and conditions. Social problems. Social reform Health care Pandemic Ethnicity Humans Medicine 030212 general & internal medicine Pandemics Minority Groups media_common health equity Clinical Trials as Topic clinical trials Equity (economics) Distrust SARS-CoV-2 business.industry 030503 health policy & services Health Policy Public Health Environmental and Occupational Health Current Debate vaccines Medical research Health equity Clinical trial Family medicine Communicable Disease Control Female Public aspects of medicine RA1-1270 0305 other medical science business Covid-19 Research Article |
| Zdroj: | Global health action, 14(1):1892309. Taylor and Francis Ltd. Global Health Action article-version (VoR) Version of Record Global Health Action, Vol 14, Iss 1 (2021) |
| ISSN: | 1654-9880 1654-9716 |
| Popis: | Coronavirus disease 2019 (COVID-19) mortality and morbidity have been shown to increase with deprivation and impact non-White ethnicities more severely. Despite the extra risk Black, Asian and Minority Ethnicity (BAME) groups face in the pandemic, our current medical research system seems to prioritise innovation aimed at people of European descent. We found significant difficulties in assessing baseline demographics in clinical trials for COVID-19 vaccines, displaying a lack of transparency in reporting. Further, we found that most of these trials take place in high-income countries, with only 25 of 219 trials (11.4%) taking place in lower middle- or low-income countries. Trials for the current best vaccine candidates (BNT162b2, ChadOx1, mRNA-173) recruited 80.0% White participants. Underrepresentation of BAME groups in medical research will perpetuate historical distrust in healthcare processes, and poses a risk of unknown differences in efficacy and safety of these vaccines by phenotype. Limiting trial demographics and settings will mean a lack of global applicability of the results of COVID-19 vaccine trials, which will slow progress towards ending the pandemic. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|